Found: 2
Select item for more details and to access through your institution.
European Post-Approval Safety Study (EU Pass) of Relapsed/Refractory Multiple Myeloma (RRMM): Safety In Patients (Pts) Treated With Pomalidomide (POM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e62, doi. 10.1016/j.clml.2017.03.113
- By:
- Publication type:
- Article
Phase 2 Multicenter Study of Pomalidomide (POM) Plus Low-Dose Dexamethasone (LoDEX) in Patients (Pts) With Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment (RI): An Updated Safety Analysis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e145, doi. 10.1016/j.clml.2017.03.261
- By:
- Publication type:
- Article